Search
Showing results for "aboriginal respiratory"
Research
Koolungar (Children) Moorditj (Strong) Healthy SkinThe Koolungar (children) Moorditj (strong) Healthy Skin project is the first ever co-designed research-service Australian study to describe skin health in urban-living Aboriginal koolungar.
Research
Characterizing the risk of respiratory syncytial virus in infants with older siblings: a population-based birth cohort studyOur results lend support to a vaccination strategy which includes family members in order to provide maximum protection for newborn babies.
Research
West Australian parents’ views on vaccinating their children against COVID-19: a qualitative studyAustralian children and adolescents were among the last local cohorts offered COVID-19 vaccines. Despite promising initial uptake, coverage subsequently plateaued, requiring further efforts to improve access and build parents’ recognition of the importance of COVID-19 vaccination.
Research
Randomised controlled trials of behavioural nudges delivered through text messages to increase influenza and COVID-19 vaccine uptake among pregnant women (EPIC study) in AustraliaInfluenza and COVID-19 vaccine uptake among pregnant women is sub-optimal. We assessed the effectiveness of a multi-component behavioural nudge intervention to improve COVID-19 and influenza vaccine uptake among pregnant women.
Research
Limited impact of neonatal or early infant schedules of 7-valent pneumococcal conjugate vaccinationEarly 7vPCV schedules have limited impact on pneumococcal vaccine type carriage in PNG
Research
The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocolCoronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.
Research
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN)This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2018 influenza season
News & Events
Australia Day Honours for researchers and esteemed ElderFour outstanding members of The Kids Research Institute Australia family – three researchers and an Aboriginal Elder co-researcher – have been named in the Australia Day Honours List for their outstanding service to research and the community.
Research
AusVaxSafetyChristopher Peter Peter Tom Blyth Jacoby Richmond Snelling MBBS (Hons) DCH FRACP FRCPA PhD BA (Hons) MSc MBBS MRCP(UK) FRACP BMBS DTMH GDipClinEpid
Research
Clinical experience with SUBA-itraconazole at a tertiary paediatric hospitalItraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking.